Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer

Alan P. Venook; Charles D. Blanke; Richard M. Goldberg; Denise K. Reinke; Susan Sutherland; John R. Taylor; Pamela McAllister; Richard L. Schilsky

doi:10.1016/S1548-5315(11)70756-2

Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer

Alan P. Venook, Charles D. Blanke, Richard M. Goldberg, Denise K. Reinke, Susan Sutherland, John R. Taylor, Pamela McAllister, Richard L. Schilsky

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

This article is the first in a new series that details available clinical trials and offers information on how you and your practice can participate. The CALGB/SWOG 80405 trial is designed to assess the optimal combination of biological agents and chemotherapy for the first-line treatment of patients with advanced or metastatic colorectal cancer.

Original language	English (US)
Pages (from-to)	593-598
Number of pages	6
Journal	Community Oncology
Volume	3
Issue number	9
DOIs	https://doi.org/10.1016/S1548-5315(11)70756-2
State	Published - Sep 2006
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/S1548-5315(11)70756-2

Cite this

@article{2df0116438c44a498628268db7f2af0f,

title = "Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer",

abstract = "This article is the first in a new series that details available clinical trials and offers information on how you and your practice can participate. The CALGB/SWOG 80405 trial is designed to assess the optimal combination of biological agents and chemotherapy for the first-line treatment of patients with advanced or metastatic colorectal cancer.",

author = "Venook, {Alan P.} and Blanke, {Charles D.} and Goldberg, {Richard M.} and Reinke, {Denise K.} and Susan Sutherland and Taylor, {John R.} and Pamela McAllister and Schilsky, {Richard L.}",

year = "2006",

month = sep,

doi = "10.1016/S1548-5315(11)70756-2",

language = "English (US)",

volume = "3",

pages = "593--598",

journal = "Community Oncology",

issn = "1548-5315",

publisher = "BioLink Communications",

number = "9",

}

TY - JOUR

T1 - Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer

AU - Venook, Alan P.

AU - Blanke, Charles D.

AU - Goldberg, Richard M.

AU - Reinke, Denise K.

AU - Sutherland, Susan

AU - Taylor, John R.

AU - McAllister, Pamela

AU - Schilsky, Richard L.

PY - 2006/9

Y1 - 2006/9

N2 - This article is the first in a new series that details available clinical trials and offers information on how you and your practice can participate. The CALGB/SWOG 80405 trial is designed to assess the optimal combination of biological agents and chemotherapy for the first-line treatment of patients with advanced or metastatic colorectal cancer.

AB - This article is the first in a new series that details available clinical trials and offers information on how you and your practice can participate. The CALGB/SWOG 80405 trial is designed to assess the optimal combination of biological agents and chemotherapy for the first-line treatment of patients with advanced or metastatic colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=33751220821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751220821&partnerID=8YFLogxK

U2 - 10.1016/S1548-5315(11)70756-2

DO - 10.1016/S1548-5315(11)70756-2

M3 - Review article

AN - SCOPUS:33751220821

SN - 1548-5315

VL - 3

SP - 593

EP - 598

JO - Community Oncology

JF - Community Oncology

IS - 9

ER -

Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this